Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) announced that the company has recently received a Drug Registration Certificate issued by the National Medical Products Administration for Valsartan Amlodipine Tablets (I). The drug is indicated for the treatment of primary hypertension and is intended for patients whose blood pressure cannot be adequately controlled with single-drug therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments